Novacyt S.A. (ALNOV) Earnings Call Transcripts

Novacyt S.A.'s Latest Earnings Call - April 8, 2026

In Q1 2026, Novacyt S.A. announced the acquisition of Southern Cross Diagnostics, a move expected to be immediately accretive to earnings. The acquisition, valued at AUD 8.5 million with a potential earn-out of AUD 16.5 million, aims to enhance Novacyt's product portfolio and regional presence in Australia and New Zealand. Revenue and earnings figures for the quarter were not disclosed in the call. The company successfully raised EUR 785,000 through a preferential subscription rights process, indicating strong shareholder support. Management emphasized cost control and potential new product launches in 2026, signaling a focus on growth and operational efficiency.

Reported metrics

Guidance from management

Management plans to launch new products in 2026 and focus on cost management. They aim to strengthen commercial partnerships and adapt to industry changes, maintaining a firm control on costs.

What analysts pressed on

Analysts expressed concerns about the geopolitical and market uncertainties impacting cash flow and investment. There were questions about how Novacyt plans to manage these risks while pursuing growth through acquisitions and new product launches.

Main topics on the call

• Acquisition of Southern Cross Diagnostics — Novacyt acquired Southern Cross Diagnostics for an initial cash consideration of AUD 8.5 million, with a contingent earn-out of up to AUD 16.5 million. The acquisition is expected to be immediately accretive and expands ...
• Shareholder Support and Capital Raise — The company raised EUR 785,000 through a preferential subscription rights process, which was oversubscribed by 25%. This indicates strong shareholder support for the acquisition and future growth plans.
• Focus on Cost Management — Management highlighted the importance of cost control, stating 'cash is even more king than it was 12 months ago.' They plan to focus on preserving cash and managing costs amid geopolitical and market uncertainties.
• Future Product Launches — Novacyt plans to launch new products in 2026 to build on the success of its reproductive health care and Ranger product ranges. This is part of a broader strategy to strengthen commercial partnerships and adapt to indust...

Read the full Novacyt S.A. transcript (April 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 9 Novacyt S.A. earnings call transcripts on record, spanning September 29, 2022 to June 30, 2026. Based on this history, Novacyt S.A. reports semi-annually. The most recent call on file is dated June 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ALNOV

Exchange

ENXTPA

Country

FR

Sector

Health Care

Industry

Biotechnology

Calls on record

9

First call

September 29, 2022

Most recent

June 30, 2026

Reporting cadence

semi-annually